You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

Claims for Patent: 8,343,952

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,343,952

Title:	Prolyl hydroxylase inhibitors and methods of use
Abstract:	The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
Inventor(s):	Wu Shengde, Warshakoon Namal C., Evdokimov Artem G., Greis Kenneth D., Boyer Angelique Sun, Kawamoto Richard Masaru
Assignee:	Akebia Therapeutics Inc.
Application Number:	US12860073
Patent Claims:	3. The compound according to claim 2 , wherein Ris —OH.4. The compound according to claim 2 , wherein Ris —OCHor —OCHCH.5. The compound according to claim 2 , wherein Ris chosen from —NH claim 2 , —NHCH claim 2 , or —N(CH).6. The compound according to claim 2 , wherein Rand Rare both hydrogen.8. The compound according to claim 7 , wherein Ris —OH.9. The compound according to claim 7 , wherein Ris —OCHor —OCHCH.10. The compound according to claim 7 , wherein Ris chosen from —NH claim 7 , —NHCH claim 7 , or —N(CH).11. The compound according to claim 7 , wherein Rand Rare both hydrogen.13. The compound according to claim 12 , wherein Ris —OH.14. The compound according to claim 12 , wherein Ris —OCHor —OCHCH.15. The compound according to claim 12 , wherein Ris chosen from —NH claim 12 , —NHCH claim 12 , or —N(CH).16. The compound according to claim 12 , wherein Rand Rare both hydrogen.18. The compound according to claim 17 , wherein Ris —OH.19. The compound according to claim 17 , wherein Ris —OCHor —OCHCH.20. The compound according to claim 17 , wherein Ris chosen from —NH claim 17 , —NHCH claim 17 , or —N(CH).21. The compound according to claim 17 , wherein Rand Rare both hydrogen.23. The compound according to claim 22 , wherein Ris —OH.24. The compound according to claim 22 , wherein Ris —OCHor —OCHCH.25. The compound according to claim 22 , wherein Ris chosen from —NH claim 22 , —NHCH claim 22 , or —N(CH).26. The compound according to claim 22 , wherein Rand Rare both hydrogen.29. The composition according to claim 28 , wherein the compound is chosen from {[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid claim 28 , {[5-(4-fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid claim 28 , {[5-(3-trifluoromethylphenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid claim 28 , and {[5-(3-chloro-6-methylphenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid.31. The composition according to claim 30 , wherein the compound is {[5-(2 claim 30 ,3-dihydrobenzo[1 claim 30 ,4]dioxin-6-yl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.